Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Identifieur interne : 000212 ( Main/Exploration ); précédent : 000211; suivant : 000213Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Auteurs : Emanuele Pontali [Italie] ; Elena Angeli ; Anna M. Cattelan ; Ivana Maida ; Paola Nasta ; Gabriella Verucchi ; Antonietta Caputo ; Claudio Iannacone ; Massimo PuotiSource :
- Antiviral therapy ; 2015.
English descriptors
- KwdEn :
- Adult, Anemia (chemically induced), Anemia (pathology), Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Cell Count, Coinfection, Female, HIV Infections (drug therapy), HIV Infections (pathology), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (physiology), Hepacivirus (drug effects), Hepacivirus (physiology), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (pathology), Hepatitis C, Chronic (virology), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Male, Middle Aged, Neutropenia (chemically induced), Neutropenia (pathology), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Ribavirin (administration & dosage), Ribavirin (adverse effects), Thrombocytopenia (chemically induced), Thrombocytopenia (pathology), Viral Load (drug effects).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemically induced : Anemia, Neutropenia, Thrombocytopenia.
- drug effects : HIV-1, Hepacivirus, Viral Load.
- drug therapy : HIV Infections, Hepatitis C, Chronic.
- pathology : Anemia, HIV Infections, Hepatitis C, Chronic, Neutropenia, Thrombocytopenia.
- physiology : HIV-1, Hepacivirus.
- virology : HIV Infections, Hepatitis C, Chronic.
- Adult, Cell Count, Coinfection, Female, Humans, Male, Middle Aged.
Abstract
Until recently, recommendations for HCV treatment in HIV-coinfected patients have been combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). However, this treatment is often accompanied with cytopenias which lead to drug-dose reduction/discontinuation, therefore influencing sustained virological response (SVR). This study aimed at evaluating incidence and predictors of cytopenias and to define their impact on SVR in Italian HIV-HCV-coinfected patients undergoing PEG-IFN/RBV treatment.
DOI: 10.3851/IMP2781
PubMed: 24831457
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000162
- to stream PubMed, to step Curation: 000162
- to stream PubMed, to step Checkpoint: 000106
- to stream Ncbi, to step Merge: 000C06
- to stream Ncbi, to step Curation: 000C06
- to stream Ncbi, to step Checkpoint: 000C06
- to stream Main, to step Merge: 000209
- to stream Main, to step Curation: 000212
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.</title><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy. pontals@yahoo.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious Diseases, Galliera Hospital, Genoa</wicri:regionArea><wicri:noRegion>Genoa</wicri:noRegion></affiliation></author><author><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name></author><author><name sortKey="Cattelan, Anna M" sort="Cattelan, Anna M" uniqKey="Cattelan A" first="Anna M" last="Cattelan">Anna M. Cattelan</name></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="doi">10.3851/IMP2781</idno><idno type="RBID">pubmed:24831457</idno><idno type="pmid">24831457</idno><idno type="wicri:Area/PubMed/Corpus">000162</idno><idno type="wicri:Area/PubMed/Curation">000162</idno><idno type="wicri:Area/PubMed/Checkpoint">000106</idno><idno type="wicri:Area/Ncbi/Merge">000C06</idno><idno type="wicri:Area/Ncbi/Curation">000C06</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C06</idno><idno type="wicri:Area/Main/Merge">000209</idno><idno type="wicri:Area/Main/Curation">000212</idno><idno type="wicri:Area/Main/Exploration">000212</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.</title><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy. pontals@yahoo.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious Diseases, Galliera Hospital, Genoa</wicri:regionArea><wicri:noRegion>Genoa</wicri:noRegion></affiliation></author><author><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name></author><author><name sortKey="Cattelan, Anna M" sort="Cattelan, Anna M" uniqKey="Cattelan A" first="Anna M" last="Cattelan">Anna M. Cattelan</name></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="e-ISSN">2040-2058</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anemia (chemically induced)</term><term>Anemia (pathology)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Cell Count</term><term>Coinfection</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (pathology)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (physiology)</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (physiology)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (pathology)</term><term>Hepatitis C, Chronic (virology)</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Neutropenia (chemically induced)</term><term>Neutropenia (pathology)</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (adverse effects)</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Thrombocytopenia (chemically induced)</term><term>Thrombocytopenia (pathology)</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Anemia</term><term>Neutropenia</term><term>Thrombocytopenia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Hepacivirus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Anemia</term><term>HIV Infections</term><term>Hepatitis C, Chronic</term><term>Neutropenia</term><term>Thrombocytopenia</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>HIV-1</term><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cell Count</term><term>Coinfection</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Until recently, recommendations for HCV treatment in HIV-coinfected patients have been combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). However, this treatment is often accompanied with cytopenias which lead to drug-dose reduction/discontinuation, therefore influencing sustained virological response (SVR). This study aimed at evaluating incidence and predictors of cytopenias and to define their impact on SVR in Italian HIV-HCV-coinfected patients undergoing PEG-IFN/RBV treatment.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name><name sortKey="Cattelan, Anna M" sort="Cattelan, Anna M" uniqKey="Cattelan A" first="Anna M" last="Cattelan">Anna M. Cattelan</name><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></noCountry><country name="Italie"><noRegion><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000212 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000212 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24831457
|texte= Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24831457" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |